A detailed history of Ray Dalio (Bridgewater Associates, LP) transactions in Schrodinger, Inc. stock. As of the latest transaction made, Bridgewater Associates, LP holds 101,159 shares of SDGR stock, worth $2.18 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
101,159
Previous 113,800 11.11%
Holding current value
$2.18 Million
Previous $4.07 Million 32.97%
% of portfolio
0.01%
Previous 0.02%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024

SELL
$24.74 - $35.13 $312,738 - $444,078
-12,641 Reduced 11.11%
101,159 $2.73 Million
Q4 2023

Feb 14, 2024

SELL
$21.62 - $37.21 $217,259 - $373,923
-10,049 Reduced 8.11%
113,800 $4.07 Million
Q3 2023

Nov 13, 2023

BUY
$27.34 - $55.37 $273,919 - $554,752
10,019 Added 8.8%
123,849 $3.5 Million
Q2 2023

Aug 11, 2023

BUY
$26.1 - $49.92 $8,978 - $17,172
344 Added 0.3%
113,830 $5.68 Million
Q1 2023

May 12, 2023

SELL
$18.09 - $27.61 $37,862 - $57,787
-2,093 Reduced 1.81%
113,486 $2.99 Million
Q4 2022

Feb 13, 2023

SELL
$16.24 - $26.38 $600,620 - $975,637
-36,984 Reduced 24.24%
115,579 $2.16 Million
Q3 2022

Nov 10, 2022

SELL
$23.95 - $34.71 $98,338 - $142,519
-4,106 Reduced 2.62%
152,563 $3.81 Million
Q2 2022

Aug 11, 2022

BUY
$21.39 - $35.9 $168,916 - $283,502
7,897 Added 5.31%
156,669 $4.14 Million
Q1 2022

May 13, 2022

BUY
$24.84 - $36.12 $895,780 - $1.3 Million
36,062 Added 32.0%
148,772 $5.08 Million
Q4 2021

Feb 14, 2022

SELL
$33.38 - $59.25 $309,499 - $549,366
-9,272 Reduced 7.6%
112,710 $3.93 Million
Q3 2021

Nov 12, 2021

SELL
$53.75 - $76.55 $171,301 - $243,964
-3,187 Reduced 2.55%
121,982 $6.67 Million
Q2 2021

Aug 13, 2021

BUY
$59.02 - $78.8 $7.39 Million - $9.86 Million
125,169 New
125,169 $9.46 Million

Others Institutions Holding SDGR

About Schrodinger, Inc.


  • Ticker SDGR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Health Information Services
  • Shares Outstandng 62,028,400
  • Market Cap $1.33B
  • Description
  • Schrödinger, Inc., together with its subsidiaries, provides physics-based software platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on selling its software for drug discovery in the life sciences i...
More about SDGR
Track Ray Dalio's Portfolio

Track Ray Dalio Portfolio

Follow Ray Dalio (Bridgewater Associates, LP) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bridgewater Associates, LP, based on Form 13F filings with the SEC.

News

Stay updated on Bridgewater Associates, LP and Ray Dalio with notifications on news.